These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29610267)

  • 1. Case of Severe Hypertension and Nephrotic Range Proteinuria.
    Bursztyn M; Touyz RM; Laffer CL; Carey RM; Dominiczak AF
    Hypertension; 2018 Jun; 71(6):956-961. PubMed ID: 29610267
    [No Abstract]   [Full Text] [Related]  

  • 2. Nephrotic range proteinuria and resistant hypertension--is it the egg that came first?
    Leiba A; Capua M; Dinour D; Adir EH; Sela BA; Holtzman EJ
    Kidney Int; 2012 Sep; 82(5):612. PubMed ID: 22892861
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of eplerenone on nephrotic syndrome in a patient with renovascular hypertension.
    Suzuki J; Otsuka F; Inagaki K; Tanabe K; Tsukamoto N; Miyoshi T; Nakamura E; Ogura T; Kumagai I; Makino H
    Hypertens Res; 2011 Mar; 34(3):404-6. PubMed ID: 21160478
    [No Abstract]   [Full Text] [Related]  

  • 4. Mineralocorticoid receptor antagonism as an add-on treatment for resistant hypertension.
    Rossi GP; Maiolino G
    Hypertens Res; 2014 Dec; 37(12):1029-31. PubMed ID: 25231253
    [No Abstract]   [Full Text] [Related]  

  • 5. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
    Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
    Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does spironolactone reduce the risk of urinary tract cancers in hypertensive patients?
    Teo KK
    J Hypertens; 2017 Jan; 35(1):36-38. PubMed ID: 27902627
    [No Abstract]   [Full Text] [Related]  

  • 7. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    Nakhoul F; Khankin E; Yaccob A; Kawachi H; Karram T; Awaad H; Nakhoul N; Hoffman A; Abassi Z
    Am J Physiol Renal Physiol; 2008 Mar; 294(3):F628-37. PubMed ID: 18094029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy.
    Gupta A; Schiros CG; Gaddam KK; Aban I; Denney TS; Lloyd SG; Oparil S; Dell'Italia LJ; Calhoun DA; Gupta H
    J Hum Hypertens; 2015 Apr; 29(4):241-6. PubMed ID: 25231508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of combined treatment with dopamine receptor agonists and antagonists of aldosterone on the performance of daily blood pressure monitoring in patients with hypertension and concomitant obesity].
    Lyzogub VG; Sobol' VO; Dolynna OV; Kuz'mins'ka LA
    Lik Sprava; 2012; (1-2):63-8. PubMed ID: 23035601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geriatrics photo quiz. Nephrotic syndrome. Proteinuria characterizes this condition, and treatment targets the underlying pathology.
    Ross JS; Shua-Haim JR
    Geriatrics; 2000 Mar; 55(3):22, 80. PubMed ID: 10732001
    [No Abstract]   [Full Text] [Related]  

  • 11. [Conn syndrome as cause of stubborn hypertension. Which hypertensives should you screen?].
    Reincke M
    MMW Fortschr Med; 2003 Feb; 145(9):37-40. PubMed ID: 12666528
    [No Abstract]   [Full Text] [Related]  

  • 12. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.
    Ghazi L; Dudenbostel T; Lin CP; Oparil S; Calhoun DA
    J Hypertens; 2016 May; 34(5):1005-10. PubMed ID: 26886564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PATHWAY-2: spironolactone for resistant hypertension.
    Dale A; Hartley P; Goldacre B;
    Lancet; 2016 Apr; 387(10026):1372-1373. PubMed ID: 27115813
    [No Abstract]   [Full Text] [Related]  

  • 14. PATHWAY-2: spironolactone for resistant hypertension.
    Gkaliagkousi E; Gavriilaki E; Triantafyllou A; Douma S
    Lancet; 2016 Apr; 387(10026):1372. PubMed ID: 27115812
    [No Abstract]   [Full Text] [Related]  

  • 15. PATHWAY-2: spironolactone for resistant hypertension.
    Boutari C; Stavropoulos K; Imprialos K; Doumas M; Karagiannis A
    Lancet; 2016 Apr; 387(10026):1371-1372. PubMed ID: 27115810
    [No Abstract]   [Full Text] [Related]  

  • 16. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.
    Morales E; Millet VG; Rojas-Rivera J; Huerta A; Gutiérrez E; Gutiérrez-Solís E; Egido J; Praga M
    Nephrol Dial Transplant; 2013 Feb; 28(2):405-12. PubMed ID: 23222416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone for resistant hypertension--hard to resist?
    Sternlicht H; Bakris GL
    Lancet; 2015 Nov; 386(10008):2032-2034. PubMed ID: 26414969
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016.
    Epstein M; Duprez DA
    Am J Med; 2016 Jul; 129(7):661-6. PubMed ID: 26899747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension: spironolactone and resistant hypertension.
    Williams JS
    Nat Rev Endocrinol; 2010 May; 6(5):248-50. PubMed ID: 20414316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.